These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

620 related articles for article (PubMed ID: 28975889)

  • 21. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures.
    Naik AM; Fey J; Gemignani M; Heerdt A; Montgomery L; Petrek J; Port E; Sacchini V; Sclafani L; VanZee K; Wagman R; Borgen PI; Cody HS
    Ann Surg; 2004 Sep; 240(3):462-8; discussion 468-71. PubMed ID: 15319717
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection.
    Borgstein PJ; Pijpers R; Comans EF; van Diest PJ; Boom RP; Meijer S
    J Am Coll Surg; 1998 Mar; 186(3):275-83. PubMed ID: 9510258
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Micro-metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure.
    Tjan-Heijnen VC; Buit P; de Widt-Evert LM; Ruers TJ; Beex LV
    Breast Cancer Res Treat; 2001 Nov; 70(2):81-8. PubMed ID: 11768607
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lymphovascular invasion is a significant risk factor for non-sentinel nodal metastasis in breast cancer patients with sentinel lymph node (SLN)-positive breast cancer: a cross-sectional study.
    Wei C; Deng Y; Wei S; Huang Z; Xie Y; Xu J; Dong L; Zou Q; Yang J
    World J Surg Oncol; 2023 Dec; 21(1):386. PubMed ID: 38097994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sentinel lymphadenectomy in node negative breast cancer.
    Haigh PI; Giuliano AE
    Cancer Treat Res; 2000; 103():25-37. PubMed ID: 10948440
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevalence and Consequences of Axillary Lymph Node Dissection in the Era of Sentinel Lymph Node Biopsy for Breast Cancer.
    Yen TWF; Laud PW; Pezzin LE; McGinley EL; Wozniak E; Sparapani R; Nattinger AB
    Med Care; 2018 Jan; 56(1):78-84. PubMed ID: 29087982
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of sentinel lymph node mapping on relative charges in patients with early-stage breast cancer.
    Gemignani ML; Cody HS; Fey JV; Tran KN; Venkatraman E; Borgen PI
    Ann Surg Oncol; 2000 Sep; 7(8):575-80. PubMed ID: 11005555
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Implementation of the Targeted Axillary Dissection Procedure in Clinically Node-Positive Breast Cancer: A Retrospective Analysis.
    Nijveldt JJ; Rajan KK; Boersma K; Noorda EM; van der Starre-Gaal J; Kate MV'V; Roeloffzen EMA; Vendel BN; Beek MA; Francken AB
    Ann Surg Oncol; 2024 Jul; 31(7):4477-4486. PubMed ID: 38523225
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Sentinel node skills verification and surgeon performance: data from a multicenter clinical trial for early-stage breast cancer.
    Posther KE; McCall LM; Blumencranz PW; Burak WE; Beitsch PD; Hansen NM; Morrow M; Wilke LG; Herndon JE; Hunt KK; Giuliano AE
    Ann Surg; 2005 Oct; 242(4):593-9; discussion 599-602. PubMed ID: 16192820
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Radiotherapy or surgery of the axilla after a positive sentinel node in breast cancer (EORTC 10981-22023 AMAROS): a randomised, multicentre, open-label, phase 3 non-inferiority trial.
    Donker M; van Tienhoven G; Straver ME; Meijnen P; van de Velde CJ; Mansel RE; Cataliotti L; Westenberg AH; Klinkenbijl JH; Orzalesi L; Bouma WH; van der Mijle HC; Nieuwenhuijzen GA; Veltkamp SC; Slaets L; Duez NJ; de Graaf PW; van Dalen T; Marinelli A; Rijna H; Snoj M; Bundred NJ; Merkus JW; Belkacemi Y; Petignat P; Schinagl DA; Coens C; Messina CG; Bogaerts J; Rutgers EJ
    Lancet Oncol; 2014 Nov; 15(12):1303-10. PubMed ID: 25439688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The Impact of Sentinel Lymph Node Biopsy on Female Patients With T3-4c Breast Cancer and 1-2 Positive Lymph Nodes: A Population-Based Cohort Study.
    Yang H; Sun Y; Wang P; Qiao J; Wang C; Liu Z
    Clin Breast Cancer; 2024 Apr; 24(3):e126-e137.e3. PubMed ID: 38114365
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The value of completion axillary treatment in sentinel node positive breast cancer patients undergoing a mastectomy: a Dutch randomized controlled multicentre trial (BOOG 2013-07).
    van Roozendaal LM; de Wilt JH; van Dalen T; van der Hage JA; Strobbe LJ; Boersma LJ; Linn SC; Lobbes MB; Poortmans PM; Tjan-Heijnen VC; Van de Vijver KK; de Vries J; Westenberg AH; Kessels AG; Smidt ML
    BMC Cancer; 2015 Sep; 15():610. PubMed ID: 26335105
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Serial sectioning of sentinel nodes in patients with breast cancer: a pilot study.
    Jannink I; Fan M; Nagy S; Rayudu G; Dowlatshahi K
    Ann Surg Oncol; 1998 Jun; 5(4):310-4. PubMed ID: 9641451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anatomy and physiology of lymphatic drainage of the breast from the perspective of sentinel node biopsy.
    Tanis PJ; Nieweg OE; Valdés Olmos RA; Kroon BB
    J Am Coll Surg; 2001 Mar; 192(3):399-409. PubMed ID: 11245383
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Axillary management in patients with breast cancer and positive axilla at diagnosis. Experience in a Spanish university hospital with a 5-year follow-up.
    Jimenez-Gomez M; Loro-Pérez J; Vega-Benítez V; Hernández-Hernández JR; Aguirre NA
    J Cancer Res Ther; 2023; 19(2):183-190. PubMed ID: 37313900
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Role of axillary lymph node dissection after tumor downstaging with induction chemotherapy for locally advanced breast cancer.
    Kuerer HM; Newman LA; Fornage BD; Dhingra K; Hunt KK; Buzdar AU; Ames FC; Ross MI; Feig BW; Hortobagyi GN; Singletary SE
    Ann Surg Oncol; 1998 Dec; 5(8):673-80. PubMed ID: 9869512
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of Targeted Axillary Dissection After Neoadjuvant Therapy in Patients With Node-Positive Breast Cancer.
    Kuemmel S; Heil J; Bruzas S; Breit E; Schindowski D; Harrach H; Chiari O; Hellerhoff K; Bensmann E; Hanf V; Graßhoff ST; Deuschle P; Belke K; Polata S; Paepke S; Warm M; Meiler J; Schindlbeck C; Ruhwedel W; Beckmann U; Groh U; Dall P; Blohmer JU; Traut A; Reinisch M
    JAMA Surg; 2023 Aug; 158(8):807-815. PubMed ID: 37285140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Characteristics and risk factors of axillary lymph node metastasis of microinvasive breast cancer.
    Lee SY; Yoo TK; Kim J; Chung IY; Ko BS; Kim HJ; Lee JW; Son BH; Lee SB
    Breast Cancer Res Treat; 2024 Aug; 206(3):495-507. PubMed ID: 38658448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. De-escalation of axillary treatment in the event of a positive sentinel lymph node biopsy in cT1-2 N0 breast cancer treated with mastectomy: nationwide registry study (BOOG 2013-07).
    de Wild SR; van Roozendaal LM; de Wilt JHW; van Dalen T; van der Hage JA; van Duijnhoven FH; Simons JM; Schipper RJ; de Munck L; van Kuijk SMJ; Boersma LJ; Linn SC; Lobbes MBI; Poortmans PMP; Tjan-Heijnen VCG; van de Vijver KKBT; de Vries J; Westenberg AH; Strobbe LJA; Smidt ML
    Br J Surg; 2024 Apr; 111(4):. PubMed ID: 38597154
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Incidence of sentinel lymph node metastases in apparent early-stage endometrial cancer: a multicenter observational study.
    De Vitis LA; Fumagalli D; Schivardi G; Capasso I; Grcevich L; Multinu F; Cucinella G; Occhiali T; Betella I; Guillot BE; Pappalettera G; Shahi M; Fought AJ; McGree M; Reynolds E; Colombo N; Zanagnolo V; Aletti G; Langstraat C; Mariani A; Glaser G
    Int J Gynecol Cancer; 2024 May; 34(5):689-696. PubMed ID: 38514100
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.